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Background/aim: It is recommended that a central venous catheter (CVC) be removed if central line-associated bloodstream infection
(CLABSI) has been diagnosed. The objective of this retrospective study was to evaluate the risk factors for recurrent CLABSI in reinserted
catheters in a pediatric intensive care unit.
Materials and methods: Patients with recurrent and nonrecurrent CLABSI were compared in terms of the catheter exchange interval,
the interval between negative blood culture and reinsertion of the CVC, and the pre-/reinsertion treatment duration.
Results: Thirty-one patients with initial CLABSI had reinserted CVCs, and 12 (38.7%) of these patients were diagnosed with recurrent
CLABSI. In the recurrent group, the catheter exchange interval, the interval between negative blood culture and reinsertion of the
second CVC, and pre-/reinsertion treatment duration were found to be shorter. Logistic regression analysis revealed that if the interval
between negative blood culture and reinsertion of the second CVC was shorter than 4 days, recurrent CLABSI risk increased by 1.7-fold
(P = 0.021). Sterile gauze-dressed patients had shorter cumulative catheter surveys than the polyurethane-dressed patients (P = 0.005).
Conclusion: Using transparent polyurethane dressings instead of sterile gauze for maintaining the CVC and delaying the reinsertion
procedure for at least 4 days after the negative culture might be helpful in preventing recurrent CLABSI.
Key words: Central line-associated bloodstream infections, risk factors for recurrence, pediatric intensive care unit

1. Introduction
Central venous catheters (CVCs) are essential for the
management of children in intensive care units. CVCs
are not only useful for the administration of medications,
blood products, parenteral nutrition, and fluid therapy;
they are also essential for invasive procedures such as
hemodynamic monitorization and plasmapheresis. One
of the most important complications of CVCs are central
line-associated bloodstream infections (CLABSIs), which
are associated with high morbidity and mortality in
addition to increased medical costs due to longer hospital
stays and the use of more expensive antimicrobial drugs
(1–3).
Once a CLABSI is suspected, general recommendations
include removal of the catheter for nontunneled CVCs
(4,5). However, in practical clinical settings, a substantial
number of patients with CLABSIs require reinsertion
of their CVCs since these patients still require reliable
persistent venous lines for their ongoing therapy. Data
related to the risk factors associated with recurrent
* Correspondence: dr.ranaisguder@yahoo.com

1128

CLABSI following catheter removal and reinsertion are
limited to a few studies, most of which focused on adult
patients only (6–8).
In this study, we focused on the risk factors of the
recurrence of CLABSI in a retrospective cohort of children
in a pediatric intensive care unit (PICU) following catheter
reinsertion.
2. Materials and methods
2.1. Study population, hospital setting, and inclusion/
exclusion criteria
In this retrospective study, the clinical data of patients
between the ages of 1 month old and 18 years old and
hospitalized at the PICU of Dr. Behçet Uz Children’s
Research and Training Hospital from July 2012 to July
2014 were collected. Dr. Behçet Uz Children’s Hospital
is a tertiary-care pediatric teaching hospital. At the time
of the study, the PICU had 24 beds and 772 patients were
hospitalized annually there. The study was approved by the
institutional research board.
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A retrospective cohort of patients with CLABSIs was
formed by using clinical data. Among the patients with
CLABSI, those who had had a reinserted, nontunneled
CVC formed the study group. Clinical findings and
microbiological data were analyzed for the risk of recurrent
CLABSI in this group.
Patients who had more than one CVC at the same
time or whose CVC duration was shorter than 48 h were
excluded from the study. Patients with persistent CLABSI
were also not enrolled in this study.
2.2. Central venous catheter insertion technique
For the catheterization process, 1, 2, or 3 lumen
polyurethane nontunneled temporary catheters (B.
Braun, Melsungen, Germany) were chosen. None of them
were antimicrobial-impregnated catheters. Before the
implementation process and according to the guidelines
of the Centers for Disease Control and Prevention (CDC),
hand hygiene was ensured and powder-free sterile gloves,
a mask, a cap, and a sterile scrub suit were worn (4). For
skin antisepsis, 10% povidone iodine or 2% chlorhexidine
solutions were used. The entire body of the patient, with
the exception of the intervention site, was covered with
sterile drapes. Catheters were inserted using the Seldinger
technique. For the dressing of the catheter site, the first
choice was a transparent polyurethane cover (Tegaderm,
3M Medical, St Paul, MN, USA) and whenever that was
not possible sterile gauze was used instead. The transparent
polyurethane cover was changed every 7 to 10 days, and
sterile gauzes were changed every 2 days.
In our clinic, the infection control committee performs
regular education sessions about catheter insertion, followup processes, disinfection during the maintenance of
catheters, and hand hygiene for all employees. We did not
use the guidewire exchange technique for implementation
of new catheters in our PICU.
2.3. Microbiologic criteria
The definition of CLABSI was based on the new CDC
definitions (9).
2.3.1. Definition of CLABSI
CLABSI is defined as a laboratory-confirmed bloodstream
infection (LCBI) for which the central line (CL) has been
in place for >2 calendar days from the date of the event,
with the day of device placement being day 1 and the CL
having been in place on the date of the event or the day
before. If the CL was in place for >2 calendar days and
was then removed, the LCBI criteria must be fully met on
the day of discontinuation or the next day. If the patient
is admitted or transferred to a facility with a CL in place
(e.g., tunneled or implanted central line), and that is the
patient’s only central line, the day of first access as an
inpatient is considered day 1. “Access” is defined as line
placement, infusion, or withdrawal through the line.

2.3.2. Definition of recurrent CLABSI
Recurrent CLABSI is defined as a new CLABSI
development occurring after catheter removal and three
negative blood cultures on consecutive days.
2.4. Data collection, study design, and statistics
Patient demographics, comorbid diseases, and PRISM 3
(Pediatric Risk of Mortality 3) scores (10) were recorded.
Type and duration of the first catheter, the isolated
microorganism, time of reproduction, and the name,
duration, and initiation day of the antibiotic or antifungal
agent and the day of the negative blood culture were all
recorded.
Type and insertion site of the second catheter,
disinfection material, catheter site dressing type used
during insertion, and the number of punctures performed
were recorded. The presence of blood transfusion or total
parenteral nutrition therapy via this catheter, the presence
of mechanical ventilation support, and the presence of
neutropenia were also noted. The isolated microorganism
thought to be the causative agent for CLABSI and the
day on which the positivity of the culture occurred were
recorded.
“Early initiation of appropriate antimicrobial
treatment” was accepted if the appropriate antimicrobial
treatment had been started within 48 h of the initial
CLABSI diagnosis. “Appropriate antimicrobial treatment”
was defined if the cultured microorganism was susceptible
to at least one of the antimicrobial agents and the therapy
was given for 10–14 days (5,7).
We defined four parameters related to catheter
reinsertion to identify the risk factors contributing to
recurrent CLABSI:
1. First CVC removal time: interval between initial
CLABSI and the removal of the first catheter.
2. Interval between negative blood culture and the
second CVC: the interval between the negative culture
obtained after the treatment of initial CLABSI and the
reinsertion of the second CVC.
3. Catheter exchange interval: the interval between the
removal of the first catheter and the implementation of the
second one.
4. Pre-/reinsertion treatment duration: the duration of
appropriate antimicrobial treatment before the reinsertion
of the second catheter.
All of the data were primarily evaluated by descriptive
statistical methods. For numeric data, the mean and
median as the measures of central tendency and the
standard deviation (SD) and interquartile range (IQR) as
measures of spread were used. The Kolmogorov–Smirnov
test and the coefficient of variation were used to assess the
distribution of the data and a histogram, stem and leaf
diagrams, and box-plot graphs were used, as well. Numeric
data were compared with the Mann–Whitney U-test and

1129

İŞGÜDER et al. / Turk J Med Sci
Student’s t-test. Categorical data were compared by using
the chi-square test and Fisher’s exact test between the
generated groups. Kaplan–Meier survival analysis was
performed to investigate the effect of the variables that had
statistically significant differences for the recurrence risk
in the catheter survey.
Variables with significant differences were analyzed by
multivariate logistic regression analysis using a backward
stepwise procedure to predict risk of recurrence. The
Hosmer–Lemeshow test was used to assess the goodness
of fit of the models. The cutoff value of numeric data
showing a significant difference was determined by using
receiver operating characteristic (ROC) curve analysis.
The sensitivity, specificity, positive predictive, and negative
predictive values of the limits were calculated in the
presence of a significant limit value. P < 0.05 was considered
statistically significant. SPSS 15.0 (SPSS Inc., Chicago, IL,
USA) was used for the corresponding procedures.
3. Results
A total of 168 patients were catheterized 265 times, and
39 were diagnosed with initial CLABSI. A CVC was then
reinserted in 31 of these 39 patients (79%), and 12 patients
(12/31; 38.7%) were diagnosed as having recurrent
CLABSI. The study group consisted of 17 females (54.8%)
and 14 males (45.2%). Their median age was 22 months
(minimum 1, maximum 166 months), and the median

hospitalization day was 195 days (minimum 19, maximum
977 days). The median PRISM 3 score was 4.19 (minimum
0, maximum 8). The most common comorbidities
were neuromuscular diseases (45.2%), cardiovascular
diseases (25.8%), metabolic diseases (22.6%), and genetic
syndromes (6.5%), respectively. The median initial
CLABSI development time was 27 days (minimum 4,
maximum 119 days). Antimicrobial therapy had been
initiated within 1.77 days (ranging from the first day to
5 days) and had been continued for 16.92 ± 4.87 days
(minimum 8, maximum 21 days). Candida parapsilosis
was the most common cause of recurrent (33.4%) and
nonrecurrent (52.6%) CLABSIs (Table 1). Nineteen of the
reinserted CVCs were subclavian (61.3%), 8 of them were
femoral (25.8%), and 4 of them were jugular (12.9%).
There was no statistically significant difference between
recurrent and nonrecurrent CLABSIs in terms of age, sex,
PRISM 3 score, hospitalization duration, and comorbid
diseases (P > 0.05). Initial CLABSI development duration,
antimicrobial treatment initiation time, and the duration
of antimicrobial therapy showed no significant difference
(P > 0.05). There was no significant difference between
the two groups in terms of means of early initiation
of antimicrobial treatment (<48 h) and duration until
removal of the first CVC (P > 0.05). No significant statistical
differences between the recurrent and nonrecurrent
groups according to the causative microorganism (fungi
vs. bacteria) were present (P > 0.05) (Table 1).

Table 1. Distribution of the microorganisms isolated at the initial CLABSI diagnosis and the reinsertion of the central venous
catheters.

Isolated microorganisms

Initial CLABSIa
(n = 39)

Fungi (n = 26; 66.7%)
Candida parapsilosis

Cases of catheter reinsertion (n = 31)
Recurrent CLABSI
(n = 12)

Nonrecurrent CLABSI
(n = 19)

P-value

10 (52.6%)

0.293

Fungi (n = 21; 67.8%)
11 (28.2%)

4 (33.4%)

Candida albicans

9 (23.1%)

2 (16.8%)

3 (15.8%)

0.65

Candida lustensia

4 (10.3%)

1 (8.3%)

0

-

Candida tropicalis

2 (5.1%)

1 (8.3%)

0

-

8 (66.8%)

13 (68.4%)

Total
Bacteria (n = 13; 33.3%)

Bacteria (n = 10; 32.2%)

Staphylococcus epidermidis

7 (18%)

1 (8.3%)

1 (5.3%)

0.63

Pseudomonas aeruginosa

3 (7.5%)

1 (8.3%)

2 (10.5%)

0.67

Serratia marcescens

1 (2.6%)

1 (8.3%)

0

-

Acinetobacter baumannii

1 (2.6%)

1 (8.3%)

0

-

Klebsiella pneumonia

1 (2.6%)

0

3 (15.8%)

Total

39 (100%)

4 (33.2%)

6 (31.6%)

: Central line-associated blood stream infection.

a
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In the recurrent CLABSI group, “catheter exchange
interval”, “interval between negative blood culture and the
second CVC”, and “pre-/reinsertion treatment duration”
were found to be significantly shorter compared to the
nonrecurrent group (P = 0.001; P = 0.001; P = 0.008).
The incidence of sterile gauze use as catheter site dressing
instead of a transparent polyurethane cover was found
to be higher in the recurrent group compared to the
nonrecurrent group (P = 0.012) (Table 2).
When nominal data were analyzed between the
recurrent and nonrecurrent groups, only catheter site
dressing material was found to be statistically significantly
different (P = 0.012). Catheter surveys of the groups with
catheter site dressed with sterile gauze and with catheter
site dressed with transparent polyurethane were compared
via Kaplan–Meier survival analysis, and the cumulative
results for the group with the catheter site dressed with
sterile gauze were found to be lower (P = 0.005) (Figure 1).
ROC analysis was performed for the “catheter exchange
interval”, “interval between negative blood culture and the
second CVC”, and “pre-/reinsertion treatment duration”.
These were found to be statistically different between
the recurrent and the nonrecurrent group in order to
determine cutoff values. The cutoff values for the catheter
exchange interval, the interval between negative blood
culture and the second CVC, and the pre-/reinsertion
treatment duration was 11.5, 4, and 10.5 days, respectively
(Table 3; Figure 2).
3.1. Comparisons between fungi and bacteria and
between recurrent and nonrecurrent CLABSI
ROC analysis was performed for 3 numerical datasets in
order to determine separate cutoff values for groups with
either bacteria cultured or fungi cultured at the time of
the first CVC. The bacteria-cultured group and the fungicultured group had cutoff values similar to each other and
similar to the general cutoff value, as well. The cutoff value
for the catheter exchange interval was found to be 11 days
(AUC: 0.91, P: 0.03, 95% CI: 0.7–0.98) for the bacteriacultured group, whereas the cutoff value for the fungicultured group was 11.5 days (AUC: 0.79, P: 0.02, 95% CI:
0.6–0.99). The interval between the negative blood culture
and the second CVC was found to be 4.5 days (AUC: 0.87,
P: 0.01, 95% CI: 0.6–0.97) in the bacteria-cultured group
whereas the same interval was found to be 4 days (AUC:
0.85, P: 0.007, 95% CI: 0.69–0.94) in the fungi-cultured
group. Cutoff values for the pre-/reinsertion treatment
period for the bacteria- and the fungi-cultured groups
were 10 days (AUC: 0.78, P: 0.003, 95% CI: 0.69–0.96)
and 10.5 days (AUC: 0.79, P: 0.002, 95% CI: 0.7–0.98),
respectively.
Independent variables that had statistically significant
differences were used to perform multivariate logistic
regression analyses for prediction of recurrence risk, and

only “interval between negative blood culture and the
second CVC” was found to be statistically significantly
different (P: 0.021, RR: 1.7, 95% CI: 1.4–5.96). In other
words, if the second CVC was reinserted in the first 4 days
after the negative blood culture was obtained, the risk of
recurrence of CLABSI increased 1.7 times.
4. Discussion
The importance of CLABSIs has remained constant
in PICUs despite improved techniques and ongoing
preventive strategies (1,11). Although the risk factors
for developing CLABSIs have been studied before (12–
16), studies focusing on the risk factors for developing
recurrent CLABSI after reinsertion of a CVC have been
limited, especially in children (6–8). In this study, we aimed
to investigate possible risk factors for the reoccurrence of
CLABSI.
Generally, the most dominant microorganisms
cultured in CLABSI cases were coagulase-negative
staphylococci; however, the incidence of Candida species
is reported to have increased in the last decade (4). In our
study, Candida species predominated in recurrent CLABSI
cases, supporting previous reports (7). Candida parapsilosis
was the most common cause of recurrent (33.4%) and
nonrecurrent (52.6 %) CLABSI, which could be due its
being the second causative agent among Candida species
in our PICU (17). Other reasons include the organism’s
growth capacity and its affinity for intravascular devices
and prosthetic materials (18,19). Chin et al. reported that
fungal CLABSIs, in contrast to bacterial infections, were
independently associated with recurrent CLABSI (7);
however, in our study we could not find such a tendency
with Candida infections compared to bacterial infections.
Once CLABSI is diagnosed, the general suggestion is
to remove the catheter, especially nontunneled ones (4,5).
However, in clinical practice, these patients are in need of
catheter reinsertion during their follow-up visits. In our
study, the recurrence of CLABSI was observed in 38.7%
of patients who had catheters reinserted. Previous studies
were limited to mostly adults.
Chin et al. conducted a study in an adult population
receiving nontunneled catheters and observed a 41.5%
recurrence rate of CLABSI (7). Erbay et al. also found a
similar rate (34%) with many catheter types in an adult
population (8). Flynn et al. reported that the recurrence
rate was as high as 44% for totally implantable CVCs,
while it was reported as 8% for tunneled catheters in their
pediatric study population (6).
We attempted to identify the possible risk factors for
recurrent CLABSIs after the first CLABSI; however, we
could not find a meaningful relationship between age, sex,
PRISM 3 scores, hospitalization duration, or comorbid
diseases and CLABSI recurrence. Previous studies
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Table 2. Comparison between the recurrent and the nonrecurrent CLABSI groups.
Recurrent
CLABSIa

Nonrecurrent
CLABSI

P-value

25 (34; 1–90)

20 (14; 1–166)

0.64

Female

4 (33.3)

13 (68.4)

Male

8 (66.7)

6 (31.6)

Age (months) [median (IQRb; min–max)]
Sex (n; %)

0.056

PRISM 3c score [median (IQR; min–max)]

4.17 (3; 2–6)

4.21 (4; 0–8)

0.96

Hospitalization day (days) [median (IQR; min–max)]

281 (434; 22–977)

140 (110; 19–484)

0.509

Neuromuscular

6 (50)

8 (42.1)

Cardiovascular

2 (16.7)

6 (31.6)

Metabolic

3 (2.5)

4 (21.1)

Genetic

1 (8.3)

1 (5.2)

Comorbid diseases (n; %)

0.66

1st CVCd
Initial CLABSI development time (days) [median (IQR; min–max)]

23 (21; 6–84)

29.6 (19; 4–119)

0.164

Initiation of the therapy after the 1st CLABSI (days) [median (IQR; min–max)]

1.67 (2; 0–4)

1.84 (1; 0–5)

0.92

Early initiation of antimicrobial treatment (<48 h) (n, %)

10 (83.3)

15 (78.9)

0.76

Antimicrobial treatment duration (days) [median (IQR; min–max)]

16.9 (7; 8–21)

19.5 (7; 10–40)

0.82

1st CVC removal time (days) [median (IQR; min–max)]

2 (3; 0–7)

2 (1; 0–4)

0.66

Catheter exchange interval (days) [median (IQR; min–max)]

7.58 (7; 3–12)

23.3 (28; 5–54)

0.001*

Interval between negative blood culture and the second CVC (days) [median
(IQR; min–max)]

2.67 (4; 0–8)

16.1 (19; 0–48)

0.001*

Pre-/reinsertion treatment period (days) [median (IQR; min–max)]

8.08 (7; 3–15)

14.95 (11; 5–35)

0.008*

Bacteria

4 (33.3)

6 (31.6)

Fungus

8 (66.7)

13 (68.4)

Yes

4 (33.3)

7 (36.8)

No

8 (66.7)

12 (63.2)

Cultured microorganism at the 1st CLABSI (n; %)
0.9

2nd CVC
Total parenteral nutrition (n; %)
0.84

Blood transfusion (n; %)
Yes

5 (41.7)

9 (47.4)

No

7 (58.3)

10 (52.6)

0.75

Mechanical ventilation support (n; %)
Yes

9 (75)

15 (78.9)

No

3 (25)

4 (21.1)

Yes

1 (8.3)

1 (5.3)

No

11 (91.7)

18 (94.7)

Subclavian

7 (58.3)

12 (63.2)

Jugular

2 (16.7)

2 (10.5)

Femoral

3 (25)

5 (26.3)

0.79

Neutropenia (n; %)
0.73

Catheter site (n; %)
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Table 2. Continued).
Number of catheter lumens (n; %)
1

7 (58.3)

16 (84.2)

≥2

5 (41.7)

3 (15.8)

1

9 (75)

11 (57.9)

≥2

3 (25)

8 (42.1)

10% povidone iodine

8 (66.7)

14 (73.7)

2% chlorhexidine

4 (33.3)

5 (26.3)

0.2

Number of punctures (n; %)
0.45

Disinfection material (n; %)
0.7

Catheter dressing (n; %)
Transparent polyurethane

5 (41.7)

17 (89.5)

Sterile gauze

7 (58.3)

2 (10.5)

: Central line-associated blood stream infection.		
: Interquartile range.				
c
: Pediatric Risk of Mortality Score 3.
a

b

0.012*

: Central venous catheter.
*: P-values found to be statistically significant (P < 0.05).

d

Figure 1. Kaplan–Meier survival analysis of catheter survival between the group with
catheter site dressed with a sterile sponge and the group with catheter site dressed with
transparent polyurethane.
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Table 3. Results of receiver operating characteristic analysis.
Cutoff value Sensitivity Specificity + Predictivity – Predictivity
AUCb P
(days)
(%)
(%)
(%)
(%)

95% CIc

Catheter exchange interval

11.5

91

73

69

93

0.842

0.002 0.7–0.98

Interval between negative blood
culture and the second CVCa

4

75

84

75

84

0.844

0.01

Pre-/reinsertion treatment duration

10.5

75

68

60

81

0.779

0.001 0.7–0.98

0.6–0.95

: Central venous catheter.
: Area under the curve.
c
: Confidence interval.
a

b

Figure 2. In this receiver operating characteristics diagram, the cutoff values,
sensitivity, specificity, and area under the curve are marked with arrows and

observed to be high.

reported more recurrence in burn patients (8), in males,
and in patients with high APACHE II scores (7), but no
linkage could be shown in multivariable models. Another
study also reported that there was no difference between
the two groups when the same variables as in our study
were used (6).
It is important to initiate antibiotic therapy as soon
as possible once CLABSI has been diagnosed (4). The
current Infectious Diseases Society of America guidelines
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recommend at least 10 to 14 days of therapy for CLABSI
(5). In our center, appropriate antibiotic therapy was
initiated in the early stages of initial CLABSI (1.77 days;
IQR: 1, minimum 0, maximum 5) and continued for
approximately 17 days on average; however, no difference
was observed between the recurrent and nonrecurrent
groups. Our findings are supported by previous reports
presented by Flynn et al., in which no difference between
the recurrent and the nonrecurrent group was found by
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means of appropriate antimicrobial therapy (6). Moreover,
Chin et al. reported that delayed administration of
appropriate antibiotics (>48 h after diagnosis of a catheterrelated bloodstream infection) was not associated with
recurrent catheter-related infections (7). These findings
suggest that appropriate therapy might be effective for
current CLABSIs; however, it does not prevent possible
recurrent CLABSIs in the future.
Current guidelines recommend the removal of the
catheter at early stages after CLABSI has been detected (4,5).
Many studies reported that the removal of the catheter at
the early stage of blood stream infection had positive effects
on mortality, especially within 72 h in the case of Candida
spp. blood stream infections (19,20). Conflicting studies
have been published since 2002 (21–23); however, in our
clinic we perform catheter removal as soon as possible. In
our study the median removal time of the CVC was 2 days
and removal time was not significantly different between
the recurrent and nonrecurrent groups.
Many risk factors have been reported for initial CLABSI
development. The site, number of lumens, type of catheter,
catheterization technique, total parenteral nutrition
administration, blood or blood products administration,
and hemodialysis via catheter were the most common risk
factors reported (12,14). Young patient age, treatment with
immunosuppressives, the presence of neutropenia, and the
presence of mechanical ventilation support were also found
to be definite risk factors for initial CLABSI development
(24,25). We hypothesized that the risk factors of recurrent
CLABSI might be the same as the risk factors of initial
CLABSI. However, we could not find a link between the
second CVC site, number of lumens, puncture numbers
during insertion, or the disinfection material and recurrent
CLABSI. The exact insertion site that will lower the risk of
infection is still being debated (4); however, in our study,
we observed that the site of insertion did not differ between
the groups.
In our study, we attempted to determine the modifiable
risk factors, but we found no statistically significant
differences between the recurrent and the nonrecurrent
groups in terms of total parenteral nutrition support,
mechanical ventilation support, blood or blood products
admission via catheter, and patients being neutropenic. Our
findings supported previous reports. Flynn et al. studied
whether catheter type, presence of sepsis, or recent bone
marrow transplantation affected recurrence risk and found
that only totally implantable catheters increased this risk
(6). Different risk factors associated with recurrent CLABSI
were defined before. Chin et al. investigated total parenteral
nutrition support, blood transfusion, the presence of
neutropenia, catheter site, and the department in which
the insertion was performed. A high risk of recurrence
was reported to be associated with procedures performed
in intensive care units (7). On the other hand, Erbay et al.

reported that blood transfusions were associated with a
higher risk of recurrence (8).
Univariate analyses for all categorical data in our study
revealed that only the sterile gauze usage rate for catheter
site dressing was statistically higher in the recurrent group.
Moreover, the cumulative catheter survey results of the
sterile gauze group were found to be lower than those
for transparent polyurethane dressings (Tegaderm). An
analysis of six studies reported a 4-fold increase in the rate of
catheter-related blood stream infection when polyurethane
dressing was used to secure the CVC (26). However, the
authors acknowledged that this research was at risk of
bias and associated with wide confidence intervals, due
to the small study population. In our relatively large-scale
study, transparent polyurethane dressing was found to be
protective against recurrent CLABSI, suggesting that more
large-scale studies are required to support our findings.
In our study, “catheter exchange interval”, “interval
between negative blood culture and the second CVC”, and
“pre-/reinsertion treatment duration” were found to be
shorter in cases of recurrent CLABSI; however, Chin et al.
reported that there was no significant difference between
these three datasets (7). On the other hand, Erbay et al.
compared the groups by catheter removal time only and
found no difference (8). In our ROC analysis, we found that
the cutoff values for “catheter exchange interval”, “interval
between negative blood culture and the second CVC”, and
“pre-/reinsertion treatment duration” were 11.5 days, 4
days, and 10.5 days, respectively. According to these results,
we postulated that if these time periods were shorter than
the determined cutoff values, the recurrence risk would
increase. However, only “interval between negative blood
culture and the second CVC” was found to be effective in the
prediction of risk of recurrence. Moreover, if a second CVC
insertion is done earlier than 4 days after the negative blood
culture has been obtained, the recurrence risk will increase
1.7 times. Thus, we recommend that the reinsertion of the
catheter be delayed at least 4 days after the negative culture.
Our study has several limitations due to its retrospective
design and heterogeneous patient characteristics. However,
since studies focusing on the recurrence of CLABSI in
children are limited, this particular study has provided
additional data to the literature concerning recurrence risks
(6).
In conclusion, a considerable number of children
whose catheters have been removed due to CLABSI will
experience recurrent CLABSI. According to our study,
using transparent polyurethane dressings instead of sterile
gauze for maintaining the CVC, coupled with delaying the
reinsertion procedure for at least 4 days after the negative
culture, might be helpful in preventing recurrent CLABSI.
Further studies are required to determine additional risk
factors and possible interventions to prevent recurrent
CLABSI.
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